Oral cancer treatment which applied the epidermal growth factor receptor degradation by catechin

2018 Fiscal Year Final Research Report

• Project/Area Number: 15K11240
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Surgical dentistry
• Research Institution: University of Fukui
• Principal Investigator: Yoshimura Hitoshi 福井大学, 学術研究院医学系部門, 准教授 (40362917)
• Project Period (FY): 2015-04-01 – 2019-03-31
• Keywords: 口腔癌 / カテキン / 増殖抑制 / アポトーシス

Outline of Final Research Achievements

EGCG is a major constituent of green tea. The aim of this study was to evaluate the therapeutic potential of EGCG for targeting human OSCC in vitro and in vivo. In the in vitro experiments, EGCG suppressed HSC-3 cell viability in a time- and dose-dependent manner. Cell cycle analysis showed that EGCG induced G1 phase arrest of the tumor cells. Treatment with EGCG significantly increased caspase 3 and 7 activities, and the percentage of apoptotic cells as compared to control cells. In the in vivo xenograft experiment on mice, EGCG treatment resulted in a 45.2% reduction in tumor size as compared with the control group. There were significant differences in Ki-67 expression between the EGCG treatment group and control group, and the percentage of apoptotic cells in the EGCG treatment group was significantly greater than that in the control group. These results indicated that EGCG significantly inhibited cell proliferation by affecting the cell cycle progression and apoptosis.

Free Research Field

口腔癌

Academic Significance and Societal Importance of the Research Achievements

口腔扁平上皮癌（OSCC）は口腔領域で最も一般的な悪性腫瘍の1つである。現在の治療戦略にもかかわらず、生存率は数十年間改善されていない。したがって、OSCCの治療への新しいアプローチを開発することは重要であった。我々の結果は、口腔癌治療への新しいアプローチとしてのエピガロカテキン-3-ガレート（EGCG）の治療応用への可能性を示唆した。